Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
MELBOURNE, Australia, Sept. 05, 2017 -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), announced today it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference. The conference is being held on September 10-12, 2017 in New York City.
The Rodman & Renshaw conference is sponsored by H. C. Wainwright & Co., a leading Wall Street investment bank, with a strong reputation in life sciences. Over 2,000 institutional and other investors are expected to attend the conference, each with a significant interest in the life sciences sector.
Dr Ross Macdonald, Managing Director and CEO, will provide an overview of the Company and its unique Cymerus™ platform during the live presentation and will also be participating in one-on-one meetings with U.S. and international investors and potential partners who are registered to attend the conference. A copy of the presentation will be made available on Cynata’s website.
If you are an institutional investor, and would like to attend the Company’s presentation, please visit the Rodman & Renshaw website to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
Event: 19th Annual Rodman & Renshaw Global Investment Conference
Date: September 11, 2017
Time: 3:00pm (US Eastern Time)
Location: Holmes II Room; Lotte New York Palace Hotel in New York City
About Cynata Therapeutics (ASX:CYP)
Cynata Therapeutics Limited (ASX:CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus’ novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata’s unique “off-the-shelf” Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.
CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, [email protected] Daniel Paproth, Australia Media Contact, 0421 858 982, [email protected] Laura Bagby, U.S. Media Contact, 312-448-8098, [email protected]
